BRCA1 and ovarian carcinoma: Hollis and colleagues summarized the evidence regarding the implications of different germline BRCA PVs in ovarian cancer and concluded that aberrations at particular BRCA1 sites could confer differential sensitivity to platinum-based chemotherapy and PARPi (14).